In short
This article discusses a clinical trial investigating the use of albutrepenonacog alfa, also known as Idelvion, in patients with severe Hemophilia B. The study aims to evaluate the effectiveness and safety of this drug in patients switching from other Factor IX treatments. Idelvion is a recombinant fusion protein that links coagulation Factor IX with recombinant albumin, potentially offering prolonged dosing intervals and improved bleeding control for patients with this rare blood disorder.
At a glance
- Drug Name
- Albutrepenonacog Alfa (Idelvion)
- Condition Treated
- Severe Hemophilia B
- Study Design
- Single arm study
- Primary Outcome
- Annualized Spontaneous Bleeding Rate (AsBR)
- Key Findings from Previous Studies
- - Prolonged dosing intervals up to 14 days; - Median AsBR of 0.00 in majority of patients; - 94% of bleeds controlled with one infusion
- Study Aims
- - Collect effectiveness and safety data; - Extend results to broader Hemophilia B population; - Compare with alternative Factor IX treatments in Taiwan
What is albutrepenonacog alfa?
Albutrepenonacog Alfa, also known by its brand name IDELVION, is a medication designed to treat a rare bleeding disorder called Hemophilia B. Hemophilia B is a genetic condition where the body doesn't produce enough of a crucial blood-clotting protein called Factor IX. This deficiency can lead to prolonged bleeding after injuries or even spontaneous bleeding episodes.
How Does It Work?
Albutrepenonacog Alfa is a recombinant fusion protein that combines two important elements: Coagulation Factor IX: This is the clotting factor that people with Hemophilia B lack. Recombinant albumin: This is a protein that helps the medication last longer in the body. By fusing these two components, scientists have created a medication that can effectively replace the missing Factor IX in patients with Hemophilia B while also providing a longer-lasting effect.
Effectiveness of albutrepenonacog alfa
Clinical trials have shown promising results for albutrepenonacog alfa: Bleeding Prevention: The majority of adult and pediatric patients using IDELVION for routine prophylaxis (preventive treatment) had a median annualized spontaneous bleeding rate (AsBR) of 0.00. This means that many patients experienced no spontaneous bleeding episodes over the course of a year. Bleeding Management: When bleeding episodes did occur, 99% were managed successfully with one or two infusions of the medication. Even more impressively, 94% of bleeds were controlled with just one infusion, regardless of the cause or location of the bleed. These results suggest that albutrepenonacog alfa is highly effective both in preventing bleeding episodes and in managing them when they do occur.
Dosing and Administration
One of the significant advantages of albutrepenonacog alfa is its extended dosing intervals. Clinical data supports that IDELVION can be used for routine prophylaxis with dosing intervals of up to 14 days. This means that patients may only need to receive the medication once every two weeks, which can significantly improve their quality of life compared to more frequent treatments.
Benefits of albutrepenonacog alfa
The use of albutrepenonacog alfa offers several potential benefits for patients with Hemophilia B: Fewer Bleeding Episodes: The low AsBR suggests that patients may experience fewer spontaneous bleeding events. Effective Bleeding Control: When bleeds do occur, they can often be managed with just one or two doses of the medication. Less Frequent Dosing: The extended dosing intervals mean patients may need fewer infusions, potentially improving their quality of life. Versatility: IDELVION can be used for prophylaxis (prevention of bleeding), treatment of active bleeding episodes, and prevention of bleeding during surgical procedures.
Ongoing Research
A clinical study is currently underway to further evaluate the effectiveness and safety of albutrepenonacog alfa in a broader population of patients with severe Hemophilia B. This study aims to: Collect data on patients switching from other Factor IX products to IDELVION Extend the results of previous clinical trials to a wider group of Hemophilia B patients Compare IDELVION with other Factor IX treatments currently available in Taiwan This ongoing research will help provide more comprehensive information about the long-term effectiveness and safety of albutrepenonacog alfa in real-world clinical settings.
